Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
In a report released on January 24, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of ...
10d
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...
Medicare covers sleep tests if you experience clinical signs and symptoms of sleep apnea, narcolepsy, or parasomnia. But there are some limitations depending on what condition is being screened for.
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback